PCI Biotech awarded NOK 13.8 million from The Research Council of Norway

Our portfolio company PCI Biotech has been granted NOK 13.8 million to the project “Photochemical vaccination – novel immunotherapy concept for treatment of cancer and infectious diseases”.   The main goal of the project is to document in a proof-of-principle clinical study in cancer patients that PCI Biotech’s photochemical internalization (PCI) technology can be used […]

Oncoimmunity granted NOK 300,000 from Innovation Norway

The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.

PCI Biotech and Ultimovacs awarded NOK 500,000 from Innovation Norway

The grant will be used to further development of the existing preclinical research collaboration of the two companies.

CEO Jónas Einarsson in E24

*From the laboratory to rocket on the stock exchange – he turns medicine to gold.*

Vaccibody raised MNOK 220

The Private Placement was significantly oversubscribed by both existing shareholders and new investors.

PCI Biotech: Successful Investigational New Drug application

PCI Biotech has received clearance by the United States Food and Drug Administration (FDA) to include patients in the US.

Nordic Naonvector raised 497 MNOK

The Private Placement was oversubscribed and attracted strong interest from both existing shareholders and new institutional investors.

Nordicna Novector

Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer

Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and execution and support the company’s efforts to identify opportunities to expand its pipeline of […]

Photocure ASA: Third Quarter 2016

Photocure delivers strong third quarter results.